Detalles de la búsqueda
1.
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Scand J Gastroenterol
; 58(8): 863-873, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36799155
2.
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Crohns Colitis 360
; 6(1): otae013, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38544907
Resultados
1 -
2
de 2
1
Próxima >
>>